- AuthorisedTherapeutic use (Phase IV)
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure – Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health Effectiveness Ancillary Study – PILOT
Researchers are comparing two common medicines, aspirin and clopidogrel, after a procedure to help people with an irregular heartbeat and kidney disease. They want to find the best way to prevent strokes while also reducing bleeding risks.
For: Atrial FibrillationPoland - Ongoing, recruitingTherapeutic use (Phase IV)
Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease (GENPAD)
This study looks at how well different blood-thinning medicines work for people with narrowed leg arteries (PAD). It compares standard care with a new approach using genetic tests to help choose the best medicine to prevent serious problems like heart attacks, strokes, or limb issues.
For: Peripheral Arterial DiseaseNetherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
Vitamin-K-Antagonist and direct thrombin inhibitor Dabigatran for thrombus resolution in left ventricular thrombus after acute STEMI: an open label randomized controlled multicenter Phase-II study
This study looks at new medicines to dissolve blood clots in the heart after a heart attack. It compares a new drug called dabigatran with a standard one, warfarin-like medicines, to see which works best and is safest for preventing further clots and strokes.
For: STEMI (ST elevation myocardial infarction) · Left ventricular thrombosisAustria - Ongoing, recruitingTherapeutic use (Phase IV)
Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary syndrome undergoing percutaneoUS coronary intervention (EPIDAURUS)
This study looks at different ways to treat people who have both an irregular heartbeat (atrial fibrillation) and have recently had a heart attack. It compares how well different medicines prevent further heart problems like strokes, while also checking for any serious bleeding.
Austria · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
This study is testing a new medicine called Milvexian for people who have recently had a heart attack or similar heart problem. We want to see if it can prevent future serious heart issues better than existing treatments, with fewer side effects.
For: Acute Coronary SyndromeNetherlands · Latvia · Denmark - Ongoing, recruitingTherapeutic use (Phase IV)
PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study
The PROMISE study looks at improving care for people who've had a heart attack but don't have blocked arteries. It checks how different treatments affect their angina (chest pain) and quality of life over a year.
For: Myocardial infarction with non-obstructive coronary arteries (MINOCA)Italy - AuthorisedTherapeutic use (Phase IV)
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure (SAFE-LAAC). Comparative Health Effectiveness Randomized Trial – PILOT Study
This study looks at how different blood-thinning medicines, aspirin and clopidogrel, work after a procedure to close off a part of the heart called the left atrial appendage. We want to find the best way to prevent strokes while also reducing bleeding, for people with an irregular heartbeat called atrial fibrillation.
For: Atrial fibrillationPoland